Form 4: HeartSciences COO Sells Shares Under Pre-Arranged Trading Plan

HeartSciences Inc.'s COO and Director, Mark T. Hilz, sold 4,416 shares of common stock for a weighted average price of $3.5374 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Mark T. Hilz, the Chief Operating Officer, Secretary, and a Director of HeartSciences Inc. (HSCS), reported a sale of common stock.
• On July 29, 2025, Mr. Hilz sold 4,416 shares of HeartSciences Inc. common stock.
• The shares were sold at a weighted average price of $3.5374 per share, with individual transaction prices ranging from $3.52 to $3.57.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan that Mr. Hilz adopted on March 18, 2025.
• Following this transaction, Mr. Hilz directly beneficially owns 4,752 shares of common stock.
• Additionally, 41 shares are indirectly beneficially owned through his daughter.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, but mitigated by the fact that it was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to adverse company news.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled and transparent approach to insider trading, which is a positive for corporate governance.

Negatives

• A key executive, the COO and Director, sold a notable number of shares (4,416 shares), which can be perceived as a lack of confidence in the company's near-term prospects, despite being pre-planned.

Risks

• The sale of shares by a high-ranking insider, even under a pre-arranged plan, could potentially lead to negative investor sentiment or speculation regarding the company's future performance.

Future Outlook

No forward-looking statements or guidance regarding the company's future performance or strategic direction are provided in this filing.

Industry Context

This filing details a routine insider transaction by a key executive and does not provide information directly related to broader industry trends or competitive landscape. It is specific to the individual's stock holdings and trading plan.

Corporate Governance

Related Party Transactions

• 41 shares are indirectly beneficially owned by the reporting person through their daughter.

Stakeholder Impact

• Shareholders may interpret the sale by a key executive as a negative signal, potentially impacting investor sentiment, although the pre-arranged nature via a 10b5-1 plan mitigates some of this concern.

Key Dates

Recommendation

The sale by a key executive was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than a reaction to new negative information. While insider selling can be a bearish signal, the pre-planned nature mitigates immediate concerns, warranting a 'hold' rather than a 'sell' unless further negative catalysts emerge or a pattern of significant insider selling develops.

Keywords

HeartSciences, HSCS, Insider Trading, Form 4, Stock Sale, Mark Hilz, 10b5-1 plan, Corporate Officer, Director, Beneficial Ownership